# Alvogen Korea clinical trials: 24 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials with Alvogen Korea as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Alvogen Korea: 24 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/alvogen-korea

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 1, 2026 | NCT07678827 | A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD | Alvogen Korea | Phase 3 | Not yet recruiting | Attention Deficit Hyperactivity Disorder, Attention-Deficit / Hyperactivity Disorder, ADHD | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678827) |
| May 18, 2022 | NCT05378503 | Phase IV Study of Qsymia in Obese Patients | Alvogen Korea | Phase 4 | Completed | Obesity | 232 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05378503) |
| October 25, 2017 | NCT03321318 | AK-R215 Pharmacokinetic Study Phase I | Alvogen Korea | Phase 1 | Unknown | Healthy | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03321318) |
| January 5, 2017 | NCT03010267 | DP-R213 Phase 1 Pharmacokinetics Study | Alvogen Korea | Phase 1 | Completed | Healthy | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03010267) |
| December 29, 2016 | NCT03005340 | A Phase 1 Drug Drug Interaction Clinical Trial of C1-R215 and C2-R215 in Healthy Male Volunteers | Alvogen Korea | Phase 1 | Unknown | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03005340) |
| November 4, 2016 | NCT02955368 | Clinical Trial to Evaluate the Efficacy and Safety of DP-R212 | Alvogen Korea | Phase 3 | Withdrawn | Hypertension, Hypercholesterolemia | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02955368) |
| June 27, 2016 | NCT02814500 | DP-R212 Pharmacokinetic Study Phase I | Alvogen Korea | Phase 1 | Unknown | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02814500) |
| June 3, 2016 | NCT02789475 | DP-R212 Pharmacokinetic Study | Alvogen Korea | Phase 1 | Unknown | Hypertension, Hyperlipidemias | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02789475) |
| May 12, 2016 | NCT02770261 | Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy | Alvogen Korea | Phase 3 | Completed | Hypertension, Cholesterolemia | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02770261) |
| May 5, 2016 | NCT02762643 | DP-R213 Pharmacokinetics Study | Alvogen Korea | Phase 1 | Completed | Healthy | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02762643) |
| April 6, 2016 | NCT02730689 | A Study to Compare the Pharmacokinetics of DP-R207 in Comparison to Each Component Administered Alone | Alvogen Korea | Phase 1 | Completed | Healthy Volunteers | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02730689) |
| March 24, 2016 | NCT02718846 | Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets | Alvogen Korea | Phase 4 | Completed | Meniere's Disease | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02718846) |
| March 15, 2016 | NCT02709187 | DP-R208 Pharmacokinetic Study | Alvogen Korea | Phase 1 | Completed | Healthy | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02709187) |
| March 14, 2016 | NCT02707224 | Clinical Trial to Compare the Pharmacokinetics of DP-R208 | Alvogen Korea | Phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02707224) |
| January 13, 2016 | NCT02654093 | A Drug-drug Interaction Study of DP-R213 | Alvogen Korea | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02654093) |
| May 15, 2015 | NCT02445352 | Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia | Alvogen Korea | Phase 3 | Completed | Primary Hypercholesterolemia | 379 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02445352) |
| March 19, 2015 | NCT02393612 | Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease | Alvogen Korea | Phase 3 | Completed | Peripheral Arterial Disease | 151 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02393612) |
| March 5, 2014 | NCT02079506 | Pharmacokinetic Drug Interaction Between Candesartan and Rosuvastatin | Alvogen Korea | Phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02079506) |
| April 20, 2012 | NCT01581320 | Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis | Alvogen Korea | Phase 3 | Completed | Postmenopausal Women With Osteoporosis | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01581320) |
| April 16, 2012 | NCT01577849 | Safety and Pharmacokinetic Characteristics of DP-R206(Vitamin D3) in Healthy Adult Volunteers | Alvogen Korea | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01577849) |
| September 7, 2011 | NCT01429688 | Pharmacokinetic / Pharmacodynamic (PK/PD) Study of Multiple Doses of DP-R202 in Healthy Volunteers | Alvogen Korea | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01429688) |
| September 7, 2011 | NCT01429675 | Safety and Pharmacokinetic Characteristics of DP-R206 in Healthy Adult Volunteers | Alvogen Korea | Phase 1 | Completed | Healthy | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01429675) |
| August 23, 2011 | NCT01421576 | Bioavailability Study of DP-R202 in Healthy Male Volunteers Under Fed Conditions | Alvogen Korea | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01421576) |
| August 23, 2011 | NCT01421563 | Safety and Pharmacokinetic Characteristics of DP-R202 in Healthy Male Volunteers | Alvogen Korea | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01421563) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 16 |
| Phase 3 | 6 |
| Phase 4 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 18 |
| Unknown | 4 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypertension | 3 |
| Attention Deficit Disorder with Hyperactivity | 1 |
| Obesity | 1 |
| Hyperlipidemias | 1 |
| Hypercholesterolemia | 1 |
| Meniere Disease | 1 |
| Peripheral Arterial Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Real estate firms in the United States](https://specstream.ai/data/businesses/real-estate-firms/united-states)
- [Caribbean restaurants in the United States](https://specstream.ai/data/businesses/caribbean-restaurants/united-states)
- [Mechanical engineering firms in the United States](https://specstream.ai/data/businesses/mechanical-engineering-firms/united-states)
- [Workers compensation law firms in the United States](https://specstream.ai/data/businesses/workers-compensation-law-firms/united-states)
- [French restaurants in the United States](https://specstream.ai/data/businesses/french-restaurants/united-states)
- [Scandinavian restaurants in the United States](https://specstream.ai/data/businesses/scandinavian-restaurants/united-states)
